6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Oncogenic metadherin is a key contributor to tumourigenesis with metadherin expression and cytoplasmic localisation previously linked to poor survival. A number of reports have shown metadherin localises specifically to nuclear speckles known to be rich in RNA-binding proteins including the splicing proteins YTHDC1, Sam68 and T-STAR, that have been shown to select alternative splice sites in mRNA of tumour-associated proteins including BRCA, MDM2 and VEGF. Here we investigate the interaction and relationship between metadherin and the splice factors YTHDC1, T-STAR and Sam68. Using a yeast two-hybrid assay and immunoprecipitation we show that metadherin interacts with YTHDC1, Sam68 and T-STAR and demonstrate that T-STAR is significantly overexpressed in prostate cancer tissue compared to benign prostate tissue. We also demonstrate that metadherin influences splice site selection in a dose-dependent manner in CD44v5-luc minigene reporter assays. Finally, we demonstrate that prostate cancer patients with higher metadherin expression have greater expression of the CD44v5 exon. CD44v5 expression could be used to discriminate patients with poor outcomes following radical prostatectomy. In this work we show for the first time that metadherin interacts with, and modulates, the function of key components of splicing associated with cancer development and progression.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The biology and role of CD44 in cancer progression: therapeutic implications

          CD44, a non-kinase transmembrane glycoprotein, is overexpressed in several cell types including cancer stem cells and frequently shows alternative spliced variants that are thought to play a role in cancer development and progression. Hyaluronan, the main ligand for CD44, binds to and activates CD44 resulting in activation of cell signaling pathways that induces cell proliferation, increases cell survival, modulates cytoskeletal changes, and enhances cellular motility. The different functional roles of CD44 standard (CD44s) and specific CD44 variant (CD44v) isoforms are not fully understood. CD44v contain additional peptide motifs that can interact with and sequester growth factors and cytokines at the cell surface thereby functioning as coreceptors to facilitate cell signaling. Moreover, CD44v were expressed in metastasized tumors, whereas switching between CD44v and CD44s may play a role in regulating epithelial to mesenchymal transition (EMT) and in the adaptive plasticity of cancer cells. Here, we review current data on the structural and functional properties of CD44, the known roles for CD44 in tumorigencity, the regulation of CD44 expression, and the potential for targeting CD44 for cancer therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review

            Background Immunohistochemistry (IHC) is a well-established, widely accepted method in both clinical and experimental parts of medical science. It allows receiving valuable information about any process in any tissue, and especially in bone. Each year the amount of data, received by IHC, grows in geometric progression. But the lack of standardization, especially on the post-analytical stage (interpreting and reporting of results), makes the comparison of the results of different studies impossible. Methods Comprehensive PubMED literature search with a combination of search words “immunohistochemistry” and “scoring system” was performed and 773 articles describing IHC results were identified. After further manual analysis 120 articles were selected for detailed evaluation of used approaches. Results Six major approaches to the interpretation and presentation of IHC analysis results were identified, analyzed and described. Conclusions The overview of the existing approaches in evaluation and interpretation of IHC data, which are provided in the article, can be used in bone tissue research and for either better understanding of existing scoring systems or developing a new one. Standard multiparametric, semiquantitative IHC scoring systems should simplify and clarify the process of interpretation and reporting of received data. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_221
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              pEF-BOS, a powerful mammalian expression vector.

                Bookmark

                Author and article information

                Journal
                Cancers (Basel)
                Cancers (Basel)
                cancers
                Cancers
                MDPI
                2072-6694
                23 August 2019
                September 2019
                : 11
                : 9
                : 1233
                Affiliations
                [1 ]Molecular Therapeutics and Diagnostics Group, University College London, London W1W 7TS, UK
                [2 ]Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
                [3 ]Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK
                [4 ]Institute for Health Sciences, Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast BT9 7AE, Ireland
                [5 ]Apoptosis and Proliferation Control Laboratory, The Francis Crick Institute, London NW1 1AT, UK
                [6 ]Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, KY 40508, USA
                Author notes
                [* ]Correspondence: b.simpson@ 123456ucl.ac.uk ; Tel.: +44-077-1465-0112
                [†]

                These authors have contributed equally to this manuscript.

                Author information
                https://orcid.org/0000-0003-3685-6110
                https://orcid.org/0000-0001-5347-5083
                https://orcid.org/0000-0003-0011-9792
                Article
                cancers-11-01233
                10.3390/cancers11091233
                6770463
                31450747
                a9735604-c907-4278-9f9e-9824fe18093b
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 July 2019
                : 21 August 2019
                Categories
                Article

                alternative splicing,cd44,ythdc1,sam68,prostate cancer
                alternative splicing, cd44, ythdc1, sam68, prostate cancer

                Comments

                Comment on this article